Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide +/- Abiraterone in mHSPC
NCT06134271Phase 2Not yet recruiting
- Start
- Nov 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of rezvilutamide in prostate cancer (PCa). Planned start Nov 2023; status: not yet recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06134271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06134271.